Overview

DEP-Ru Regimen as a Salvage Therapy for HLH

Status:
Unknown status

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This study aimed to investigate the efficacy and safety of ruxolitinib together with liposomal doxorubicin, etoposide and methylprednisolone (DEP-Ru) as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis.

Phase:

Phase 3

Details

Lead Sponsor:

Beijing Friendship Hospital

Treatments:

Methylprednisolone